NCT01161498 - Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Squamous Cell CarcinomaHead and Neck Cancer

Interventions

BIOLOGICAL

Talimogene Laherparepvec

Administered by intratumoral injection

RADIATION

Radiation

70 grays of radiation administered in 35 fractions over 7 weeks

DRUG

Cisplatin

Administered by intravenous infusion

Trial Locations (6)

VCU Massey Cancer Center, Richmond

Medical Univesity of South Carolina, Charleston

James Graham Brown Cancer Center, University of Louisville, Louisville

Gabrail Cancer Center, Canton

Investigative Clinical Research of Indiana, Indianapolis

The Royal Marsden Hospital, London